Kiousi Eftychia, Lyraraki Vasiliki, Mardiki Georgia Lamprini, Stachika Nikolina, Damianou Aikaterini Konstantina, Malainou Christina Panagiotis, Syrigos Nikolaos, Gomatou Georgia, Kotteas Elias
Oncology Unit, Third Department of Medicine, Sotiria General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Cancers (Basel). 2023 Nov 26;15(23):5589. doi: 10.3390/cancers15235589.
The introduction of immune checkpoint inhibitors in the therapeutics of non-small cell lung cancer (NSCLC) has been a game-changer in the management of patients with lung cancer; however, challenges do exist since a non-negligible subset of patients does not respond to therapy. Various immunotherapeutic anticancer strategies have been increasingly developed in recent years, including monoclonal antibodies, adoptive T-cell therapy, and vaccines. Fueled by their rapid drug development and successful implementation during the COVID-19 pandemic, messenger RNA (mRNA) vaccines represent an emerging therapeutic approach in other fields of medicine, including oncology. Several clinical trials are currently being conducted to assess the safety and efficacy of mRNA vaccines regarding a variety of solid tumors. Combining mRNA vaccines with other immunotherapeutic approaches has also been suggested and is currently under investigation. Although, in the case of NSCLC, the investigation is still in its early stages, the initial results raise the need for clinician awareness of these promising therapies. To this end, in the present review, we aim to summarize current advances in the development of mRNA vaccines in NSCLC therapeutics and discuss pragmatic challenges regarding their drug development and the different opportunities for implementation.
免疫检查点抑制剂引入非小细胞肺癌（NSCLC）治疗领域，改变了肺癌患者的治疗格局；然而，由于不可忽视的一部分患者对治疗无反应，挑战依然存在。近年来，各种免疫治疗抗癌策略不断发展，包括单克隆抗体、过继性T细胞疗法和疫苗。信使核糖核酸（mRNA）疫苗在COVID-19大流行期间迅速发展并成功应用，这推动了其在包括肿瘤学在内的其他医学领域成为一种新兴的治疗方法。目前正在进行多项临床试验，以评估mRNA疫苗对多种实体瘤的安全性和有效性。也有人建议将mRNA疫苗与其他免疫治疗方法相结合，目前这方面正在研究中。尽管在NSCLC方面，研究仍处于早期阶段，但初步结果表明临床医生需要了解这些有前景的疗法。为此，在本综述中，我们旨在总结NSCLC治疗中mRNA疫苗开发的当前进展，并讨论其药物开发面临的实际挑战以及不同的实施机会。
